Interestingly, mutation of several of these residues to non-phosphorylatable amino acids are found in cancer samples (S483G and S483R in breast ductal carcinoma; T484P in clear cell renal cell carcinoma; S499P in malignant melanoma; Cosmic v92; [52]), which might indicate that the phosphorylation status of DYRK2 is relevant for its activity in tumor cells. Here, DYRK2 is linked to clear cell renal carcinoma.